Liu Z D, Lockwood M, Rose S, Theobald A E, Hider R C
Department of Pharmacy, King's College London, SE1 8WA, London, UK.
Biochem Pharmacol. 2001 Feb 1;61(3):285-90. doi: 10.1016/s0006-2952(00)00551-7.
3-Hydroxypyridin-4-ones are currently one of the main candidates for the development of orally active iron chelators. Small bidentate ligands tend to inhibit iron-containing metalloenzymes and therefore can cause undesirable side effects. A range of 3-hydroxypyridin-4-ones with different R2 substituents was selected for the investigation of the structure-activity relationship between the chemical nature of the ligand and the inhibition of mammalian tyrosine hydroxylase. Results indicated that lipophilicity was the dominant factor in controlling the ability of this class of chelator to inhibit mammalian tyrosine hydroxylase. Ligands with hydrophilic R2 substituents tended to be weak inhibitors. No significant correlation was found in this study between iron-binding affinity, extended R2 chain length, and enzyme inhibitory activity. In contrast, both the LogP values of the entire molecule and of the R2 segment correlated well with inhibitory activity.
3-羟基吡啶-4-酮是目前开发口服活性铁螯合剂的主要候选物之一。小的双齿配体往往会抑制含铁金属酶,因此可能会引起不良副作用。选择了一系列具有不同R2取代基的3-羟基吡啶-4-酮,以研究配体的化学性质与对哺乳动物酪氨酸羟化酶抑制作用之间的构效关系。结果表明,亲脂性是控制这类螯合剂抑制哺乳动物酪氨酸羟化酶能力的主导因素。具有亲水性R2取代基的配体往往是弱抑制剂。在本研究中,未发现铁结合亲和力、延长的R2链长度与酶抑制活性之间存在显著相关性。相比之下,整个分子和R2片段的LogP值均与抑制活性密切相关。